Nature Clinical Practice Oncology

• Pharmacogenomic Progress in Individualized Dosing of Key Drugs in Cancer Determining the correct dosage for chemotherapeutic agents presents a challenge because there is a fine balance between doses that cause significant drug toxicity and loss of efficacy.
  Nature Clinical Practice Oncology, March 01, 2009
• Prophylactic and Therapeutic Anticoagulation for Thrombosis in Oncology Venous thromboembolism (VTE) is a major cause of morbidity and mortality in patients with cancer. Authors discuss the optimal duration of anticoagulant therapy, treatment of recurrent VTE and more.
  Nature Clinical Practice Oncology, February 01, 2009
• Capecitabine: Have We Got the Dose Right? This review summarizes why there may not be a universally applicable dose for capecitabine because of interpatient differences in basic physiology, pharmacogenomics and diet.
  Nature Clinical Practice Oncology, January 01, 2009
• Cetuximab for Recurrent and Metastatic SCCHN Metastatic squamous cell carcinoma of the head and neck carries a poor prognosis, but does cetuximab offer clinical benefits beyond those of platinum-based therapies?
  Nature Clinical Practice Oncology, December 01, 2008
• Therapy Insight: Management of CV Disease in Patients With Cancer Authors discuss management strategies for cardiovascular disease in patients with cancer, focusing on the prevention and treatment of congestive heart failure and myocardial infarction.
  Nature Clinical Practice Oncology, November 01, 2008
• Intermittent Androgen Blockade as Standard Therapy in Prostate Cancer Over 80 percent of men with advanced prostate cancer respond to standard treatment with continuous androgen deprivation therapy. Why should it be the standard?
  Nature Clinical Practice Oncology, October 01, 2008
• Hormonal Therapy and Hormonal-Receptor-Positive Breast CA With HER2 What progress has been made in understanding resistance to endocrine therapy? Insights into the management of patients with HER2-positive advanced breast cancer are presented.
  Nature Clinical Practice Oncology, September 01, 2008
• Chemotherapy for Muscle-invasive Bladder Cancer Multi-modal treatment for invasive bladder cancer has been shown to be effective, however, definitive evidence is still lacking. Learn more about combination therapies and how they affect survival.
  Nature Clinical Practice Oncology, August 01, 2008
• Lumpectomy and Irradiation for Early-stage Breast Cancer Post Hodgkin's Irradiation for Hodgkin's lymphoma increases the risk of breast cancer. A case report of a 57-year-old woman details this latent disease trajectory.
  Nature Clinical Practice Oncology, July 01, 2008
• Rapamycin Treatment for a Child With Germline PTEN Mutation Proteus syndrome is a rare hamartoma syndrome characterized by germline PTEN mutations. How effective is oral rapamycin therapy for its treatment?
  Nature Clinical Practice Oncology, June 01, 2008
• Should Adjuvant Imatinib Be Used as Primary Treatment for GIST? Gastrointestinal stromal tumor metastases can be controlled by imatinib but not by systemic chemotherapy/radiotherapy. Can imatinib be used as adjuvant therapy in GIST patients at risk for metastases?
  Nature Clinical Practice Oncology, May 01, 2008
• Metastasis: A Therapeutic Target for Cancer Metastasis remains the major driver of mortality in patients with cancer. Learn why the time is ripe for metastasis and metastatic colonization to enter mainstream clinical development and testing.
  Nature Clinical Practice Oncology, April 01, 2008
• Main Site of Origin for Malignancies Detected During Risk-Reducing Surgery BRCA-positive women may opt to undergo prophylactic surgery to reduce the risk of ovarian cancer. What are the location and frequency of malignancies that are identified at the time of the surgery?
  Nature Clinical Practice Oncology, March 01, 2008
• Gastrointestinal Stromal Tumor (GIST)--Solid Tumor Model for Cancer Therapy Gastrointestinal stromal tumors are among the first solid tumors for which cancer-(cell-)specific therapy became available. What is its pathogenesis, therapy strategies and drug resistance mechanisms?
  Nature Clinical Practice Oncology, February 01, 2008
• False-positivity of the Sentinel Node in Melanoma Will all positive sentinel lymph nodes progress to palpable nodal recurrence if not removed?
  Nature Clinical Practice Oncology, January 01, 2008
• Prophylactic Surgery Prevents Endometrial/Ovarian Cancer in Lynch Syndrome What's the rationale for prophylactic gyn surgery in women with mismatch-repair mutation causal to Lynch syndrome post-childbearing with testing and surveillance unless and until such surgery is done?
  Nature Clinical Practice Oncology, December 01, 2007
• Stereotactic Radiotherapy for Stage I Non-Small-Cell Lung Cancer Should stage I non-small-cell lung cancer patients who are unsuitable for surgery receive hypofractionated stereotactic radiotherapy? How safe is this form of radiation treatment?
  Nature Clinical Practice Oncology, November 01, 2007
• Molecular Imaging can Accelerate Anti-Angiogenic Drug Development and Test Angiogenesis is regulated by numerous molecular pathways that could serve as targets for molecular imaging. What is the role of molecular imaging in anti-angiogenic drug development?
  Nature Clinical Practice Oncology, August 28, 2007
• Surgery Insight: Surgical Management of Pancreatic Cancer Pancreatic ductal adenocarcinoma's most important treatment modality is surgery, but it is a complex procedure. What technical improvements have made pancreatic surgery safer? What are the challenges?
  Nature Clinical Practice Oncology, September 01, 2007
• Is Stereotactic Radiosurgery the Best Treatment Option for Patients Single-fraction stereotactic radiosurgery is an effective treatment for patients with brain tumors and brain metastases. How about for patients with spinal metastases?
  Nature Clinical Practice Oncology, July 01, 2007